FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
Evidence visual
Tirzepatide evidence and risk matrix
intermediate researcher fit
Evidence
Tier A
Risk
medium
Regulatory
rx approved
WADA
none
FDA
flagged
Route
subcutaneous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
Tirzepatide is a dual incretin agonist targeting both GLP-1 and GIP receptors. Clinical data show strong weight-loss and glycemic outcomes, often exceeding semaglutide in comparative datasets. Main caveat: unofficial or compounded sourcing carries the same quality and dosing concerns FDA has highlighted for this class.
Decision path
Where Tirzepatide fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Tirzepatide belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Dual GIP and GLP-1 receptor agonism increases insulin secretion, reduces glucagon, suppresses appetite, and improves metabolic control.
subcutaneous
Approved human use: 2.5 mg to 15 mg weekly subcutaneous with titration.
Large reductions in HbA1c and body weight in approved-use populations, with reduced appetite and improved metabolic markers.
Metabolic effects begin within weeks; major body-composition changes accrue over months.
Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, pregnancy, and other glucose-lowering drugs.
GI intolerance is most common: nausea, vomiting, diarrhea, constipation, and appetite suppression. Gallbladder and pancreatitis concerns remain relevant.
Additive hypoglycemia risk with insulin or secretagogues. Delayed gastric emptying can affect oral-drug absorption timing.
Cost at a glance
Typical cycle cost
$200.00
Estimated monthly
$200.00
Protocol style
Continuous / ongoing
Continuous
Estimate confidence
Moderate confidence
Assumes roughly 10 mg–20 mg per cycle, using 1 tracked affiliated listing.
Modeled as an ongoing monthly therapy based on long-duration obesity trials.
Age, sex, and monitoring
Life-stage fit
Most relevant in adult metabolic-health and obesity contexts rather than early-life performance use.
Best fit age ranges: 35-44, 45-54, 55-64
Sex-specific note
Broad adult metabolic-use case with no clean sex-based dosing difference, but similar reproductive caution as other incretin therapies.
female
Avoid in pregnancy or active conception planning unless a clinician specifically directs otherwise.
Monitoring burden
mediumMonitoring looks similar to other incretin therapies, with more attention to metabolic response and GI tolerance.
Baseline labs and checks
CMP, fasting glucose or HbA1c, lipids, weight and blood pressure baseline
Follow-up cadence
Early tolerance review, then periodic metabolic follow-up every few months.
Red flags
- persistent GI intolerance
- rapid dehydration
- pancreatitis-type abdominal pain
Known Interactions
Do not layer GLP-1 / dual-incretin agonists in a consumer stack; GI burden and dosing complexity rise without a clear rationale.
Dual incretin and GLP-1-only agonists should not be stacked in consumer protocols.
Two high-potency incretin agonists compound GI and glucose-management risk.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Tirzepatide.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.